Akaal Pharma is a clinical-stage drug discovery and development Australian biopharmaceutical company. We are developing treatment of pruritus and inflammatory skin diseases as topical drugs. Akaal’s oral drug development is focused on neuropathy/pain and autoimmune skin diseases. Akaal Pharma multimodal action products are safe and efficacious in human patients with atopic dermatitis and psoriasis.
Akaal Pharma applies its proprietary medicinal chemistry and drug discovery platform coupled with broad and in-depth drug discovery and development expertise of leadership team to search innovative, First-in-Class, technologies. Akaal Pharma has strong portfolio of patents on its internally discovered drug candidates and is continue building and strengthening the intellectual property.
The oral drug candidate is potent and selective S1P1 modulator has shown a superior profile in preclinical and in Phase-1 clinical trial.
Akaal Pharma NCE is being developed as First-in-Class treatment for pruritus and skin diseases.
Business Partnering
Akaal Pharma is developing novel, safer and highly effective drug candidates for the treatment of diseases with significantly large unmet medical need. Akaal Pharma’s drug pipeline contains innovative small molecule drugs for the treatment of pruritus, neuropathic pain, inflammatory skin diseases and autoimmune indications.
Akaal Pharma’s business strategy is to partner its proprietary products with pharmaceutical and biotech companies for clinical development, manufacturing and commercialization of its novel drugs in exchange for upfront fees, research and development funding, milestone payments and potential royalties on product sales. Please contact Akaal Pharma for further details on various partnering opportunities.